Skip to main content
SpringerLink
Log in

IgE als Zielstruktur für therapeutische Intervention

  • Chapter
Allergologie

  • 6522 Accesses

Zusammenfassung

Therapieprinzipien, die IgE, IgE-Rezeptorbindung oder IgE-Signaltransduktion als Zielstruktur nutzen, greifen am Ende der immunologischen Reaktionskaskade ein und verhindern die IgE-vermittelte Aktivierung von Effektorzellen der allergischen Entzündung. Möglichkeiten zur therapeutischen Intervention bestehen I) in der Blockade der IgE-vermittelten Aktivierung von Effektorzellen durch Reduktion des freien IgE und/oder Verhinderung der Bindung an den IgE-Rezeptor, II) Hemmung der IgE-Bildung durch gezielte Elimination von IgE-positiven B-Zellen oder III) Hemmung der IgE/FcεRI-vermittelten Signaltransduktion. Therapeutische Konzepte reichen von monoklonalen Antikörpern gegen freies, zirkulierendes IgE (z. B. Omalizumab, QGE031), löslichen FcεRI-Fusionsproteinen, Anti-IgE-DARPins (»designed ankyrin repeat proteins«) und Anti-IgE DARPin-IgG1-Fc-Fusionsproteinen, bis hin zur IgE-Plasmapherese. Während manche Ansätze schon fest im klinischen Alltag etabliert sind (z. B. Omalizumab), befinden sich viele noch in der klinischen oder präklinischen Entwicklung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Baumann MJ, Eggel A, Amstutz P, Stadler BM, Vogel M (2010) DARPins against a functional IgE epitope. Immunol Lett 133: 78–84

    Google Scholar 

  • Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grütter MG, Plückthun A (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22: 575–582

    Google Scholar 

  • Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J (2013) The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 107: 1141–1151

    Google Scholar 

  • Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR, Wong T, Chen Y, Ultsch M, Luis E, Ramani SR, Jackman J, Gonzalez L, Dennis MS, Chuntharapai A, DeForge L, Meng YG, Xu M, Eigenbrot C, Lee WP, Refino CJ, Balazs M, Wu LC (2010) Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest 120: 2218–2229

    Google Scholar 

  • Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE (2012) Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb. Immunol Lett 143(1): 34–43

    Google Scholar 

  • Chowdhury PS, Chen Y, Yang C, Cook KE, Nyborg AC, Ettinger R, Herbst R, Kiener PA, Wu H (2012) Targeting the junction of CεmX and ε-migis for the specific depletion of mIgE-expressing B cells. Mol Immunol 52: 279–288

    Google Scholar 

  • Dhaliwal B, Yuan D, Pang MOY, Henry AJ, Cain K, Oxbrow A, Fabiane SM, Beavil AJ, McDonnell JM, Gould HJ, Sutton BJ (2012) Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. Proc Natl Acad Sci USA 109: 12686–12691

    Google Scholar 

  • Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M (2011) Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 66: 961–968

    Google Scholar 

  • Feichtner S, Inführ D, Achatz-Straussberger G, Schmid D, Karnowski A, Lamers M, Rhyner C, Crameri R, Achatz G (2008) Targeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo. J Immunol 180: 5499–5505

    Google Scholar 

  • Gould HJ, Sutton BJ (2008) IgE in allergy and asthma today. Nat Rev Immunol 8: 205–217

    Google Scholar 

  • Gunneriusson E, Samuelson P, Ringdahl J, Grönlund H, Nygren PA, Ståhl S (1999) Staphylococcal surface display of immunoglobulin A (IgA)- and IgE-specific in vitro-selected binding proteins (affibodies) based on Staphylococcus aureus protein A. Appl Environ Microbiol 65: 4134–4140

    Google Scholar 

  • Haak-Frendscho M, Ridgway J, Shields R, Robbins K, Gorman C, Jardieu P (1993) Human IgE receptor α-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo. J Immunol 151: 351–358

    Google Scholar 

  • Holdom MD, Davies AM, Nettleship JE, Bagby SC, Dhaliwal B, Girardi E, Hunt J, Gould HJ, Beavil AJ, McDonnell JM, Owens RJ, Sutton BJ (2011) Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI. Nat Struct Mol Biol 18: 571–576

    Google Scholar 

  • Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosén K (2013) Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132: 101–109

    Google Scholar 

  • Kepley CL, Taghavi S, Mackay G, Zhu D, Morel PA, Zhang K, Ryan JJ, Satin LS, Zhang M, Pandolfi PP, Saxon A. (2004) Co-aggregation of FcγRII with FcεRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem 279: 35139–35149

    Google Scholar 

  • Kerzel S, Zemlin M, Rogosch T, Ollert M, Renz H, Klaus G, Maier RF.(2011) Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years. Klin Padiatr 223: 356–359

    Google Scholar 

  • Kim B, Eggel A, Tarchevskaya SS, Vogel M, Prinz H, Jardetzky TS (2012) Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature 491: 613–617

    Google Scholar 

  • Kraft S, Kinet JP (2007) New developments in FcεRI regulation, function and inhibition. Nat Rev Immunol 7: 365–378

    Google Scholar 

  • Laffer S, Lupinek C, Rauter I, Kneidinger M, Drescher A, Jordan JH, Krauth MT, Valent P, Kricek F, Spitzauer S, Englund H, Valenta R (2008) A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells. Allergy 63: 695–702

    Google Scholar 

  • Lin LH, Zheng P, Yuen JW, Wang J, Zhou J, Kong CQ, Peng X, Li J, Li L (2012) Prevention and treatment of allergic inflammation by an Fcγ-Der f2 fusion protein in a murine model of dust mite-induced asthma. Immunol Res 52: 276–283

    Google Scholar 

  • Liu Y, Sun Y, Chang LJ, Li N, Li H, Yu Y, Bryce PJ, Grammer LC, Schleimer RP, Zhu D (2013) Blockade of peanut allergy with a novel Ara h 2-Fcγ fusion protein in mice. J Allergy Clin Immunol 131: 213–221

    Google Scholar 

  • de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; Spanish Registry (2013) Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma 50: 296–301

    Google Scholar 

  • Lowelll CA (2011) Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol 3: a002352

    Google Scholar 

  • Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P (2011) Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 128: 202–209

    Google Scholar 

  • Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368: 924–935

    Google Scholar 

  • Mendonsa SD, Bowser MT (2004) In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. Anal Chem 76: 5387–5392

    Google Scholar 

  • Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L (2011) Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol 7: 9

    Google Scholar 

  • Metz M, Maurer M (2012) Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol 12: 406–411

    Google Scholar 

  • Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, Siebenhaar F, Weller K, Zuberbier T, Maurer M (2011) Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 154: 177–180

    Google Scholar 

  • Rigby LJ, Trist H, Snider J, Hulett MD, Hogarth PM, Rigby LJ, Epa VC (2000) Monoclonal antibodies and synthetic peptides define the active site of FcεRI and a potential receptor antagonist. Allergy 55: 609–619

    Google Scholar 

  • Rudolf MP, Vogel M, Kricek F, Ruf C, Zürcher AW, Reuschel R, Auer M, Miescher S, Stadler BM (1998) Epitope-specific antibody response to IgE by mimotope immunization. J Immunol 160: 3315–3321

    Google Scholar 

  • Saban R, Haak-Frendscho M, Zine M, Ridgway J, Gorman C, Presta LG, Bjorling D, Saban M, Jardieu P (1994) Human FcεRI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 94: 836–843

    Google Scholar 

  • Scheppler L, Vogel M, Marti P, Müller L, Miescher SM, Stadler BM (2005)Intranasal immunisation using recombinant Lactobacillus johnsonii as a new strategy to prevent allergic disease. Vaccine 23: 1126–1134

    Google Scholar 

  • Shankar T, Petrov AA (2013) Omalizumab and hypersensitivity reactions. Curr Opin Allergy Clin Immunol 13: 19–24

    Google Scholar 

  • Stadler BM, Zürcher AW, Miescher S, Kricek F, Vogel M (1999) Mimotope and anti-idiotypic vaccines to induce an anti-IgE response. Int Arch Allergy Immunol 118: 119–121

    Google Scholar 

  • Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV (1996) Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379: 346–349

    Google Scholar 

  • Wiegand TW, Williams PB, Dreskin SC, Jouvin MH, Kinet JP, Tasset D (1996) High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J Immunol 157: 221–230

    Google Scholar 

  • Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A (2004) Inhibition of allergen-specific IgE reactivity by a human Ig Fc gamma-Fc epsilon bifunctional fusion protein. J Allergy Clin Immunol 114: 321–327

    Google Scholar 

  • Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A (2002) A novel human immunoglobulin Fcγ–Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat Med 8: 518–521

    Google Scholar 

  • Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A (2005) A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 11: 446–449

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Engineering, Aarhus University, 8000, Aarhus C, Dänemark

    E. Spillner Prof. Dr. rer. nat.

  2. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Gießen, Gaffkystr. 14, 35385, Gießen, Deutschland

    T. Jakob Prof. Dr. med.

  3. Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Hauptstraße 7, 79104, Freiburg, Deutschland

    M. Lamers Dr. rer. nat.

Authors
  1. M. Lamers Dr. rer. nat.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Spillner Prof. Dr. rer. nat.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Jakob Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinikum rechts der Isar, Technischen Universität München, München

    Tilo Biedermann

  2. Städtisches Klinikum Karlsruhe, Karlsruhe

    Werner Heppt

  3. Universitätsklinikum Gießen und Marburg GmbH, Marburg

    Harald Renz

  4. Universitätsklinikum Tübingen, Eberhard Karls Universität, Tübingen

    Martin Röcken

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lamers, M., Spillner, E., Jakob, T. (2016). IgE als Zielstruktur für therapeutische Intervention. In: Biedermann, T., Heppt, W., Renz, H., Röcken, M. (eds) Allergologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37203-2_58

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37203-2_58

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37202-5

  • Online ISBN: 978-3-642-37203-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation